Table 1. Mutations in PcG and... | American Society of Hematology

Table 1.

Mutations in PcG and PcG-associated genes in hematological malignancies

Malignancy	EZH2, %	EED, %	SUZ12, %	ASXL1, %	Reference
MDS	3-13	Rare	Rare	10.6-18.5	50-55
MPNs	3 (PV)	Rare	Rare	1-3 (ET/PV)	51,56-58
MPNs	5-13 (PMF)			25 (PMF)
MDS/MPNs	8-15.6	1	1.4	15.6-43	51,58
AML	Rare	Rare	Rare	9-18	51,60,61
DS-AMKL	32.7	0	2	2	76
T-ALL*	18	ND	7	0	78
ETP-ALL†	12.7	12.7	17.5	0	77
Non-ETP†	3.3-4.8	3.3-7	0-2.4	0	77,79

Malignancy	EZH2, %	EED, %	SUZ12, %	ASXL1, %	Reference
MDS	3-13	Rare	Rare	10.6-18.5	50-55
MPNs	3 (PV)	Rare	Rare	1-3 (ET/PV)	51,56-58
MPNs	5-13 (PMF)			25 (PMF)
MDS/MPNs	8-15.6	1	1.4	15.6-43	51,58
AML	Rare	Rare	Rare	9-18	51,60,61
DS-AMKL	32.7	0	2	2	76
T-ALL*	18	ND	7	0	78
ETP-ALL†	12.7	12.7	17.5	0	77
Non-ETP†	3.3-4.8	3.3-7	0-2.4	0	77,79

DS-AMKL, acute megakaryoblastic leukemia associated with Down syndrome; ET, essential thrombocythemia; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; ND, not determined; PMF, primary myelofibrosis; PV, polycythemia vera.

Adults

†

Children.

View Large

This Feature Is Available To Subscribers Only